John K. Leighton

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Martin H. Cohen, Grant Williams, John R. Johnson et al. · PubMed · 2002 · 469 citations

Medicine, Pharmacokinetics, Pharmacology +13

Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

Edvardas Kaminskas, Ann Farrell, Sophia Abraham et al. · Clinical Cancer Research · 2005 · 424 citations

Medicine, Hematology, Pharmacology +15

An FDA oncology analysis of antibody-drug conjugates

Haleh Saber, John K. Leighton · Regulatory Toxicology and Pharmacology · 2015 · 172 citations

Pharmacy, Oncology, Pharmaceutics +14

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

Maitreyee Hazarika, Xiaoping Jiang, Qi Liu et al. · Clinical Cancer Research · 2008 · 135 citations

Medicine, Hematology, Pharmacology +13

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

Lawrence J. Lesko, Ronald A. Salerno, Brian B. Spear et al. · The Journal of Clinical Pharmacology · 2003 · 123 citations

Medicine, Pharmacology, Pharmaceutical Regulation +15